have devised a CRAFITY scoring model that leveraged two clinically established biomarkers: C‐reactive protein and AFP.[52] This model offers a rapid and precise means of predicting the therapeutic response to immunotherapy in patients with liver cancer. Here, AFP is linked to liver cancer.